87 related articles for article (PubMed ID: 19072641)
1. Pharmaco(epi)genomics in ovarian cancer.
Paige AJ; Brown R
Pharmacogenomics; 2008 Dec; 9(12):1825-34. PubMed ID: 19072641
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
[TBL] [Abstract][Full Text] [Related]
3. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.
Chetty C; Rao JS; Lakka SS
Pharmacogenomics; 2011 Apr; 12(4):535-46. PubMed ID: 21521025
[TBL] [Abstract][Full Text] [Related]
5. Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
Anticancer Res; 2010 Nov; 30(11):4451-8. PubMed ID: 21115892
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
Marsh S
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S30-4. PubMed ID: 19955911
[TBL] [Abstract][Full Text] [Related]
7. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
9. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
10. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
[TBL] [Abstract][Full Text] [Related]
11. The epigenetics of ovarian cancer drug resistance and resensitization.
Balch C; Huang TH; Brown R; Nephew KP
Am J Obstet Gynecol; 2004 Nov; 191(5):1552-72. PubMed ID: 15547525
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas.
Shai RM; Reichardt JK; Chen TC
Future Oncol; 2008 Aug; 4(4):525-34. PubMed ID: 18684063
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of importance for paclitaxel chemotherapy.
Green H
Pharmacogenomics; 2008 Jun; 9(6):671-4. PubMed ID: 18518845
[TBL] [Abstract][Full Text] [Related]
14. Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Methods Mol Biol; 2013; 1049():35-51. PubMed ID: 23913207
[TBL] [Abstract][Full Text] [Related]
15. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.
Helleman J; Jansen MP; Burger C; van der Burg ME; Berns EM
Int J Biochem Cell Biol; 2010 Jan; 42(1):25-30. PubMed ID: 19854294
[TBL] [Abstract][Full Text] [Related]
16. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
Glinsky GV
J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic discovery approaches: will the real genes please stand up?
Walgren RA; Meucci MA; McLeod HL
J Clin Oncol; 2005 Oct; 23(29):7342-9. PubMed ID: 16145062
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor genes associated with drug resistance in ovarian cancer (review).
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2013 Jul; 30(1):3-10. PubMed ID: 23660957
[TBL] [Abstract][Full Text] [Related]
19. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
Lum E; Vigliotti M; Banerjee N; Cutter N; Wrzeszczynski KO; Khan S; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Gynecol Oncol; 2013 Aug; 130(2):369-76. PubMed ID: 23684582
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of multidrug resistance of ovarian cancer].
Miedzińska-Maciejewska M; Wcisło G
Przegl Lek; 2002; 59(10):854-8. PubMed ID: 12632928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
